The company overtook early GLP-1 leader Novo Nordisk. Eli Lilly is increasingly reliant on its GLP-1 drugs. Eli Lilly (NYSE: ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly and Company (NYSE:LLY)’s popular drug Mounjaro will be added to China’s state-run health insurance program starting ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

The European Medicines Agency's committee on Friday recommended a change to extend the use of Eli Lilly's blockbuster drug Mounjaro for the treatment of type 2 diabetes in adolescents and children ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

The European Medicines Agency’s, EMA, committee recommended a change to extend the use of Eli Lilly’s (LLY) Mounjaro for the treatment of type 2 ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.